At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 213 enrolled
Drug / intervention
SB204 2% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled Study Comparing the Efficacy, Tolerability, and Safety of SB204 Gel and Vehicle Gel Once or Twice Daily in the Treatment of Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating SB204 2%, SB204 4%, and 1 other intervention for Acne Vulgaris. Completed, enrolled 213 participants across 20 sites.
Detailed Summary
This is a randomized, multi-center, double-blinded study in subjects with moderate to severe acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2 concentrations of a topical drug in development or a vehicle. Subjects will be treated for up to 12 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartNov 2014
Primary CompletionJun 2015
Study CompletionAug 2015
TodayJul 2026
First PostedSep 17, 2014
Enrollment StartNov 1, 2014
Primary CompletionJun 1, 2015
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 11.8 years ago
Interventions
SB204 2%drug
Applied topically twice daily
SB204 4%drug
Applied topically daily
Vehicle Geldrug
Applied topically twice and once daily